<DOC>
	<DOCNO>NCT01749319</DOCNO>
	<brief_summary>The primary objective study characterize baclofen pharmacokinetics follow oral intravenous administration patient chronic oral baclofen therapy . The secondary objective determine safety profile IV baclofen formulation . This study randomize crossover study two treatment arm . All subject receive dose oral baclofen dose IV baclofen separate study day . Whether oral intravenous form give first study day randomize 1:1 manner . The pharmacokinetic tolerability information gain study support development study assess use IV baclofen prevent treat baclofen withdrawal syndrome .</brief_summary>
	<brief_title>Oral IV Baclofen Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Substance Withdrawal Syndrome</mesh_term>
	<criteria>Subjects eligible participate study follow condition exist : 1 . Males female age 1865 . 2 . Subjects capable give informed consent . 3 . Female subject must postmenopausal least 1 year , surgically incapable bearing child , practice least one follow method contraception three month prior , study : hormonal , intrauterine device ( IUD ) , barrier method combination spermicide . 4 . Subject medication free , study drug , 48 hour 24 hour study drug administration . If need medication identify time period , discuss approve PI . Subjects exclude participation study follow condition exist : 1 . Women pregnant . 2 . Women breast feeding . 3 . Subject history intolerance IV administration medication . 4 . Subject know hypersensitivity baclofen . 5 . Subject significant history cardiac , neurologic , psychiatric , oncologic , endocrine , metabolic , renal hepatic disease 6 . Subject take used investigational drug device 30 day prior screen . 7 . Subject take either prescribed counter medication 48 hour prior baclofen administration either study day . 8 . Subject reveals clinically significant abnormality screen laboratory test . 9 . Subject nonEnglish speaker , ability ascertain neurological status would require interpreter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>baclofen , withdrawal , interuption , spasticity , pharmacokinetics , tolerability , intravenous , oral</keyword>
</DOC>